BridgeBio’s Potential Cardiomyopathy Treatment Can’t Cross the Phase 3 Finish Line

BridgeBio’s investigational cardiomyopathy molecule acoramidis (AG10) fell short of the phase 3 finish line this week, when it not only failed its primary endpoint, but was associated with decreases in a functional measure of cardiac fitness relative to placebo.
Source: Drug Industry Daily